Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IPHABullishCorporate Developmentsnews

High materiality9/10

Innate-Sobi deal advances lacutamab toward accelerated approval, unlocking milestone upside

Aug 10, 2026, 2:03 AM EDT3 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The upfront $75M cash, plus near-term and potential milestone payments, de-risks liquidity and adds optionality around lacutamab's value; exclusive rights upon approval enhance upside. However, material upside requires successful TELLOMAK-3 results and regulatory approvals, with closing contingent on antitrust clearance.

AI summary

What happened, with direct paths to the underlying reporting

Innate Pharma and Sobi announced a strategic partnership to initiate TELLOMAK-3, the Phase 3 CTCL confirmatory trial for lacutamab, targeting accelerated approval in Sézary syndrome. Innate will receive $75 million at closing and could collect up to $505 million in milestones plus royalties, while Sobi gains exclusive global rights upon approval. Closing is contingent on antitrust clearance.

Innate and Sobi initiate TELLOMAK-3 Phase 3 CTCL trial.
Aims to support accelerated lacutamab approval in Sézary syndrome.
Sobi gets exclusive global commercialization rights upon approval.
Upfront $75M; milestones up to $505M; tiered double-digit royalties.
Closing is subject to anti-trust clearance.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.